SCHEMBL29626440

SCHEMBL29626440

COC(=O)/C=C/CCCCCC/C=C/C(=O)OC

nearest known ligand 0.55

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 2/20 0.55
KEAP1 Q14145 1/20 0.55
NFE2L2 Q16236 1/20 0.55
MAPT P10636 1/20 0.47
ALDH1A1 P00352 2/20 0.45
LMNA P02545 1/20 0.45
CNR1 P21554 1/20 0.41
CNR2 P34972 1/20 0.41
PPARG P37231 2/20 0.40
PPARA Q07869 2/20 0.40
EPHX2 P34913 1/20 0.39
PRKCA P17252 4/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31681514 1.00 HCAR2 (0.55) HCAR2KEAP1NFE2L2MAPTALDH1A1
SCHEMBL29626505 0.93 HCAR2 (0.57) HCAR2KEAP1NFE2L2MAPTALDH1A1
SCHEMBL347470 0.92 PPARG (0.51) MAPTLMNACNR1CNR2PPARG
SCHEMBL14672999 0.92 PPARG (0.51) MAPTLMNACNR1CNR2PPARG
SCHEMBL3710792 0.92 PPARG (0.51) MAPTLMNACNR1CNR2PPARG
SCHEMBL25405291 0.92 HCAR2 (0.46) HCAR2KEAP1NFE2L2MAPTALDH1A1
SCHEMBL22555479 0.92 PPARG (0.51) MAPTLMNACNR1CNR2PPARG
SCHEMBL21952141 0.92 MAPT (0.59) HCAR2KEAP1NFE2L2MAPTALDH1A1
SCHEMBL22555434 0.92 PPARG (0.51) MAPTLMNACNR1CNR2PPARG
SCHEMBL11743976 0.92 PPARG (0.51) MAPTLMNACNR1CNR2PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12377407-B2 Compositions and methods for visible-light-controlled ruthenium-catalyzed olefin metathesis THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2025-08-05 US disclosed
US-20220219155-A1 Compositions And Methods For Visible-Light-Controlled Ruthenium-Catalyzed Olefin Metathesis THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2022-07-14 US disclosed
US-11331656-B2 Compositions and methods for visible-light-controlled ruthenium-catalyzed olefin metathesis THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2022-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11331656-B2 Compositions and methods for visible-light-controlled ruthenium-catalyzed olefin metathesis PPOX, CYBA, CYBB HCAR2 4210/4885KEAP1 394/4885NFE2L2 186/4885
US-12377407-B2 Compositions and methods for visible-light-controlled ruthenium-catalyzed olefin metathesis PPOX, CYBA, CYBB HCAR2 4210/4885KEAP1 394/4885NFE2L2 186/4885
US-20220219155-A1 Compositions And Methods For Visible-Light-Controlled Ruthenium-Catalyzed Olefin Metathesis PPOX, CYBA, CYBB HCAR2 4210/4885KEAP1 394/4885NFE2L2 186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.